As of 3:59pm ET
| +0.02 / +0.36%|
The 4 analysts offering 12-month price forecasts for BioCryst Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 8.00. The median estimate represents a +63.34% increase from the last price of 5.51.
The current consensus among 5 polled investment analysts is to Buy stock in BioCryst Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.